A Multicenter, Open-label, Single Arm Study to Evaluate the Immunological Efficacy and Safety of GC3110A. Administered Intramuscularly in Healthy Subjects Aged 65 Years and Older
Phase of Trial: Phase III
Latest Information Update: 02 Jan 2018
At a glance
- Drugs GC 3110A (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors GC Pharma; Green Cross
- 02 Jan 2018 According to a GC Pharma media release, Green Cross Corporation rebrands itself to GC Pharma.
- 24 May 2017 Status changed from active, no longer recruiting to completed.
- 23 Nov 2016 Status changed from recruiting to active, no longer recruiting.